Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
ROCKVILLE, MD, May 07, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at Deutsche Bank's 43rd Annual Health Care Conference in Boston on May 8, 2018 at 8:00 am (ET).
A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
